article · PubMed
Diamond Blackfan Anaemia is a sporadic, inherited condition presenting shortly after birth with a broad spectrum of clinical anomalies. Inherited primarily in an autosomal dominant manner, it stems from mutations and deletions in genes encoding large or small ribosomal proteins. This disruption causes an imbalance between ribosomal RNA synthesis and ribosomal proteins, leading to the activation and stabilisation of the p53 pathway. Clinical diagnosis remains challenging because patients frequently exhibit variable and partial phenotypes. Even so, molecular testing reveals a heterozygous mutated gene in up to half of all identified cases. Corticosteroid medications currently serve as the cornerstone of therapeutic management. Furthermore, the bone marrow dysfunction observed in individuals with this condition shares broad connections with both congenital and acquired human bone marrow failure syndromes.
Understanding Diamond Blackfan Anaemia is vital because its inconsistent symptoms make early clinical diagnosis difficult for medical practitioners. Clarifying how ribosomal protein mutations activate the p53 pathway helps link the disorder to broader bone marrow failure syndromes, assisting healthcare providers in diagnosing affected infants and managing patient care through existing treatments such as corticosteroids.
The abstract mentions molecular diagnostic methods that identify relevant gene mutations in up to half of cases, alongside established corticosteroid treatments. While diagnostic laboratories and pharmaceutical researchers could potentially target ribosomal protein defects and the p53 pathway, the abstract does not indicate an explicit commercial application pathway or technology readiness level.
AI-generated from the published abstract. Always read the original work before citing.
Diamond Blackfan Anaemia (DBA) is a sporadic inherited anemia with broad spectrum of anomalies that are presented soon after delivery. It is inherited mainly in autosomal dominant inheritance manner and caused by mutations and deletions in either large or small ribosomal protein genes that results in an imbalance between the biosynthesis of rRNA and ribosomal proteins, eventually the activation and stabilization of p53. Diagnosing DBA is usually problematic due to a partial phenotype and its wide inconsistency in its clinical expression; however, molecular studies have identified a heterozygous mutated gene in up to 50% of the DBA cases and corticosteroid drugs are the backbone treatment options of DBA. Anomalies in bone marrow function in DBA cases are broadly associated with both congenital and acquired bone marrow failure syndromes in human. In this review different literatures were searched in Medline (eg. PubMed, PMC, Hinari, Google scholar), OMIM, EMBASE by using search engines (Google, Yahoo, Baidu Ask.com) and searching was performed by using search key words (DBA, ribosomopathies, Bone Marrow Failure Syndromes, pure red cell aplasia). Only human studies were included. This review is summarizing the current understandings of DBA.
This page summarises published work. The authoritative version sits with the publisher.
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
